|
Delayed
Berne S.E.
|
5-day change | 1st Jan Change | ||
| - CHF | -.--% |
|
-.--% | - |
| Market Cap | 5.48B 4.75B 4.49B 4.06B 7.63B 526B 7.68B 53.56B 20.6B 267B 20.58B 20.13B 850B | P/E 2026 * |
42.2x | P/E 2027 * | 23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 3.61B 3.13B 2.96B 2.68B 5.02B 346B 5.06B 35.27B 13.57B 175B 13.55B 13.25B 560B | EV / Sales 2026 * |
2.87x | EV / Sales 2027 * | 2.42x |
| Free-Float |
92.69% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PTC Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Matthew Klein
CEO | Chief Executive Officer | 54 | 2023-03-21 |
Pierre Gravier
DFI | Director of Finance/CFO | 41 | 2023-07-12 |
| Chief Tech/Sci/R&D Officer | - | 2017-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 2004-10-31 | |
Allan Jacobson
CHM | Chairman | 80 | 1998-03-30 |
David Southwell
BRD | Director/Board Member | 65 | 2005-11-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 5.48B | |
| -0.19% | +1.09% | +51.85% | +97.36% | 1,013B | |
| +0.33% | -0.71% | +50.62% | +65.50% | 644B | |
| +0.49% | +5.73% | +20.88% | +72.92% | 465B | |
| -0.22% | +2.88% | +38.48% | +37.98% | 352B | |
| -0.07% | +1.82% | +16.57% | +23.39% | 264B | |
| -0.31% | +2.02% | +6.15% | +10.75% | 253B | |
| -1.53% | -4.46% | +36.90% | +44.08% | 203B | |
| -1.60% | -5.51% | -22.30% | -58.60% | 188B | |
| +0.49% | -0.23% | +30.00% | +93.34% | 181B | |
| Average | -0.07% | -1.08% | +25.46% | +42.97% | 395.97B | |
| Weighted average by Cap. | +0.40% | +0.01% | +34.52% | +59.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.26B 1.09B 1.03B 933M 1.75B 121B 1.76B 12.29B 4.73B 61.18B 4.72B 4.62B 195B | 1.38B 1.19B 1.13B 1.02B 1.92B 132B 1.93B 13.45B 5.17B 66.93B 5.17B 5.05B 213B |
| Net income | 148M 128M 121M 110M 206M 14.21B 208M 1.45B 557M 7.21B 557M 544M 22.98B | 222M 192M 182M 165M 309M 21.28B 311M 2.17B 834M 10.79B 833M 815M 34.42B |
| Net Debt | -1.87B -1.62B -1.53B -1.39B -2.6B -179B -2.62B -18.29B -7.04B -91.01B -7.03B -6.87B -290B | -2.15B -1.86B -1.76B -1.59B -2.99B -206B -3.01B -20.97B -8.07B -104B -8.06B -7.88B -333B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PTCT Stock
- P91 Stock
Select your edition
All financial news and data tailored to specific country editions
